<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We studied the diagnostic role of CFC assays in <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) using CFC data from bone marrow (BM) and peripheral blood (PB) of 221 MDS patients, 51 patients with non-malignant causes of cytopenia and/or <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and 50 <z:mpath ids='MPATH_458'>normal</z:mpath> controls </plain></SENT>
<SENT sid="1" pm="."><plain>A consistent decrease in BM but not PB multi-lineage and erythroid progenitor frequencies was seen in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> compared to controls (P&lt;0.05) </plain></SENT>
<SENT sid="2" pm="."><plain>Automated distinction showed a sensitivity of 87+/-6% and a specificity of 71+/-11% in classifying <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients </plain></SENT>
<SENT sid="3" pm="."><plain>In conclusion, a defect in early hematopoietic progenitor activity, in particular erythroid activity, distinguishes <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> from non-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>